What was the primary purpose of this debt offering for Eli Lilly?

The primary purpose of this debt offering was to raise capital. The approximately $8.94 billion in net proceeds will likely be used to fund general corporate purposes, which can include ongoing research and development, strategic investments, potential acquisitions, and managing existing debt obligations.

What are the key risks associated with the notes issued in this offering?

Key risks include interest rate risk for the fixed-rate notes, as rising interest rates could make these notes less attractive. For the floating rate notes, investors face the risk of fluctuating interest payments based on SOFR. A significant risk highlighted in the filing is the potential 'Centessa Special Mandatory Redemption' for several series of notes, which could occur if the Centessa Acquisition does not close under specific conditions, leading to an early redemption at a premium.

How does the 'Centessa Special Mandatory Redemption' work?

If the Centessa Acquisition is not completed by March 31, 2027 (or a later agreed date), or if Eli Lilly decides not to proceed with the acquisition, certain specified notes (2029 Floating Rate Notes, 2029 Notes, 2031 Notes, 2033 Notes, and 2036 Notes) will be mandatorily redeemed. The redemption price will be 101% of the principal amount, plus any accrued and unpaid interest.

What is the significance of the notes being registered on Form S-3?

Registering the offering on Form S-3 indicates that Eli Lilly is a well-established public company ('well-known seasoned issuer') that meets specific SEC requirements. This allows the company to efficiently issue additional securities using a shelf registration statement, providing flexibility to access capital markets when needed without filing a new registration statement for each offering.

LLY 8-K SEC Disclosure — May 20, 2026

Summary

Eli Lilly and Company (LLY) has announced the successful completion of a significant debt offering, raising approximately $8.94 billion in net proceeds. This offering comprised multiple tranches of both floating rate and fixed rate notes with varying maturity dates and interest rates, ranging from 2028 to 2066. The issuance of these notes was registered under a Form S-3 shelf registration statement, indicating Lilly's proactive capital management strategy. The substantial capital infusion is poised to support the company's ongoing operations, strategic initiatives, and potential future investments. A notable aspect of this offering is the conditional mandatory redemption for certain series of notes tied to the consummation of the 'Centessa Acquisition'. Should this acquisition not proceed under specified conditions, specific series of notes will be subject to redemption at 101% of their principal amount, plus accrued interest, highlighting a potential contingent liability for the company dependent on M&A outcomes.

Key Highlights

1Completed a debt offering, raising approximately $8.94 billion in net proceeds.
2Issued a combination of Floating Rate Notes due 2028 and 2029, and Fixed Rate Notes with maturities spanning 2029 to 2066.
3Floating Rate Notes bear interest based on Compounded SOFR plus a spread of 0.350% or 0.460%.
4Fixed Rate Notes offer coupon rates ranging from 4.150% to 5.700%.
5The offering was conducted under an Underwriting Agreement with major financial institutions including Morgan Stanley, Citigroup, Deutsche Bank, and Goldman Sachs.
6Certain notes (2029 Floating Rate, 2029, 2031, 2033, and 2036 Fixed Rate Notes) are subject to a 'Centessa Special Mandatory Redemption' if the Centessa Acquisition is not consummated by specified dates or if Lilly decides not to pursue it, redeemable at 101% of principal plus accrued interest.

ELI LILLY & Co 8-K Report, Corporate Update (May 20, 2026)

Summary

Key Highlights

Frequently Asked Questions